Systemic lupus erythematosus

被引:0
|
作者
Jessica J Manson
Anisur Rahman
机构
[1] University College London,Centre for Rheumatology Research, Windeyer Building
来源
Orphanet Journal of Rare Diseases | / 1卷
关键词
Systemic Lupus Erythematosus; Fibromyalgia; Lupus Nephritis; Central Nervous System Disease; Peripheral Nervous System Involvement;
D O I
暂无
中图分类号
学科分类号
摘要
Systemic lupus erythematosus (SLE) is a clinically heterogeneous disease, which is autoimmune in origin and is characterized by the presence of autoantibodies directed against nuclear antigens. It is a multi-system disease, and patients can present in vastly different ways. Prevalence varies with ethnicity, but is estimated to be about 1 per 1000 overall with a female to male ratio of 10:1. The clinical heterogeneity of this disease mirrors its complex aetiopathogenesis, which highlights the importance of genetic factors and individual susceptibility to environmental factors. SLE can affect every organ in the body. The most common manifestations include rash, arthritis and fatigue. At the more severe end of the spectrum, SLE can cause nephritis, neurological problems, anaemia and thrombocytopaenia. Over 90% of patients with SLE have positive anti-nuclear antibodies (ANA). Significant titres are accepted to be of 1:80 or greater. SLE is a relapsing and remitting disease, and treatment aims are threefold: managing acute periods of potentially life-threatening ill health, minimizing the risk of flares during periods of relative stability, and controlling the less life-threatening, but often incapacitating day to day symptoms. Hydroxychloroquine and non-steroidal anti-inflammatory drugs are used for milder disease; corticosteroids and immunosuppressive therapies are generally reserved for major organ involvement; anti-CD20 monoclonal antibody is now used in patients with severe disease who has not responded to conventional treatments. Despite enormous improvements in prognosis since the introduction of corticosteroids and immunosuppressive drugs, SLE continues to have a significant impact on the mortality and morbidity of those affected.
引用
收藏
相关论文
共 50 条
  • [21] Recognition and Management of Systemic Lupus Erythematosus
    Johann O. Schroeder
    Hans H. Euler
    Drugs, 1997, 54 : 422 - 434
  • [22] Systemic Lupus Erythematosus for Primary Care
    Kado, Ruba
    PRIMARY CARE, 2018, 45 (02): : 257 - +
  • [23] Genetics and systemic lupus erythematosus.
    Tsao B.P.
    Grossman J.M.
    Current Rheumatology Reports, 2001, 3 (3) : 183 - 190
  • [24] Silent nephritis in systemic lupus erythematosus
    Zabaleta-Lanz, M
    Vargas-Arenas, RE
    Tápanes, F
    Daboin, I
    Pinto, JA
    Bianco, NE
    LUPUS, 2003, 12 (01) : 26 - 30
  • [25] Systemic lupus erythematosus and pregnancy.
    Zauner, I
    Rother, E
    Schollmeyer, P
    NIEREN-UND HOCHDRUCKKRANKHEITEN, 1995, 24 (12) : 683 - 685
  • [26] Malignancy and systemic lupus erythematosus.
    Bernatsky S.
    Clarke A.
    Ramsey-Goldman R.
    Current Rheumatology Reports, 2002, 4 (4) : 351 - 358
  • [27] Mycophenolate mofetil and systemic lupus erythematosus
    Doria, A.
    Iaccarino, L.
    Arienti, S.
    Rampudda, M. E.
    Canova, M. G.
    Rondinone, R.
    Todesco, S.
    LUPUS, 2006, 15 (11) : 44 - 54
  • [28] miRNAs in the Pathogenesis of Systemic Lupus Erythematosus
    Qu, Bo
    Shen, Nan
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2015, 16 (05) : 9557 - 9572
  • [29] Transcriptomic studies of systemic lupus erythematosus
    Nakano, Masahiro
    Iwasaki, Yukiko
    Fujio, Keishi
    INFLAMMATION AND REGENERATION, 2021, 41 (01)
  • [30] Treatment of systemic lupus erythematosus with cyclophosphamide
    Backhaus, M
    Hiepe, F
    ZEITSCHRIFT FUR RHEUMATOLOGIE, 1997, 56 (04): : 178 - 189